Abstract

BackgroundSerum and urine metabolites have been investigated for their use as cancer biomarkers. The specificity of candidate metabolites can be limited by the impact of other disorders on metabolite levels. In particular, the increasing incidence of obesity could become a significant confounding factor.MethodsHere we developed a multinomial classifier for the stratification of cancer, obesity and healthy phenotypes based on circulating glucose and formate levels. We quantified the classifier performance from the retrospective analysis of samples from breast cancer, lung cancer, obese individuals and healthy controls.ResultsWe discovered that circulating formate levels are significantly lower in breast and lung cancer patients than in healthy controls. However, the performance of a cancer classifier based on formate levels alone is limited because obese patients also have low serum formate levels. By introducing a multinomial classifier based on circulating glucose and formate levels, we were able to improve the classifier performance, reaching a true positive rate of 79% with a false positive rate of 8%.ConclusionsCirculating formate is reduced in HER2+ breast cancer, non-small cell lung cancer and highly obese patients relative to healthy controls. Further studies are required to determine the relevance of these observations in other cancer types and diseases.

Highlights

  • Serum and urine metabolites have been investigated for their use as cancer biomarkers

  • Within the range of metabolites analysed in previous studies, no single metabolite alone can be used to discriminate between samples from cancer patients and healthy controls in a reliable

  • By introducing a multinomial classifier based on glucose and formate levels, we were able to improve the classifier performance, reaching a true positive rate of 79% with a false positive rate of 8%

Read more

Summary

Introduction

Serum and urine metabolites have been investigated for their use as cancer biomarkers. In the context of cancer, several studies have been conducted with the aim of identifying serum or urine metabolites that could distinguish cancer patients from healthy controls [2,3,4,5]. We hypothesised that formate levels could be utilised to screen for cancer disease in the human population. To test this hypothesis, we performed metabolite analysis of serum/plasma samples from a Spanish cohort of breast cancer patients, lung cancer patients, obesity patients and healthy controls. In contrast to our observations in mice, circulating formate levels are significantly lower in cancer patients than in healthy controls. By introducing a multinomial classifier based on glucose and formate levels, we were able to improve the classifier performance, reaching a true positive rate of 79% with a false positive rate of 8%

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.